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Jiadifenolide has been reported to have neurotrophin-like activity in primary rat cortical neurons, and
also possesses neurotrophic effects in neuronal precursor cells derived from human induced pluripotent
stem cells (hiPSCs), as we have previously reported. However, the molecular mechanisms by which
jiadifenolide exerts its neurotrophic effects in rat and human neurons are unknown. Thus, we aimed to
investigate the molecular mechanisms and pathways by which jiadifenolide promotes neurotrophic
effects. Here, we found that jiadifenolide activated cellular communication network factor (CCN)
signaling pathways by up-regulating mRNA level expression of CCN genes in human neuronal cells. We
also found that CCN2 (also known as connective tissue growth factor, CTGF) protein promotes neuro-
trophic effects through activation of the p44/42 mitogen-activated protein kinase signaling pathway. This
is the first discovery which links neurotrophic activity with CCN signaling.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neurotrophic factors (neurotrophins) such as nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), and glial cell line-derived neurotrophic
factor (GDNF) have been reported to prevent neuronal degenera-
tion, promote neurite regeneration and neuronal survival, and
enhance synaptic plasticity [1,2]. Thus, neurotrophins have been
expected to gain approval for therapeutic applications iny, Faculty of Pharmaceutical
ihamaBouji, Yamashirocho,
y, Faculty of Pharmaceutical
ihamaBouji, Yamashirocho,
(M. Shoji), kuzuhara@ph.
Inc. This is an open access article uneurological diseases that show neurodegenerative, behavioral,
and psychiatric symptoms [3,4]. However, clinical trials of various
neurotrophic factors have been failed by which neurotrophic fac-
tors possesses high molecular weights, the limited serum-stability,
and fail to achieve adequate blood-brain-barrier (BBB) penetration
[2,5e9]. W. M. Pardridge suggested in 2012 that small-molecules
having a molecular weight (MW) of less than 400 Da and capable
of forming eight or fewer hydrogen bonds may cross the BBB via
lipid-mediated diffusion [10]. Therefore, novel small BBB-
penetrating molecules with neurotrophin-like activity are needed
to overcome the pharmacological disadvantages of peptide neu-
rotrophic factors.
Jiadifenolide and its derivatives have been reported to promote
neurite outgrowth in primary cultured rat cortical neurons [11], and
enhance NGF activity, thereby facilitating PC12 rat adrenal pheo-
chromocytoma cell differentiation [12]. In addition, we previously
reported that jiadifenolide promotes neurite outgrowth, andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells derived from human pluripotent stem cells (hiPSCs) [13]. Jia-
difenolide has aMWof 310.11 Da, and two hydrogen bond donors in
its chemical structure, thus possessing the properties of a small
molecule that are expected to give it high BBB permeability [13]. It
can also be synthesized in gram quantities using as few as eight
steps [14]. Therefore, jiadifenolide is a strong potential drug
candidate for clinical evaluation for treatment of human neuro-
logical disorders. However, the molecular mechanisms by which it
exerts its neurotrophic effects in rat and human neurons are
unknown.
The cellular communication network factor (CCN) family con-
sists of the CCN proteins, CCN1, CCN2, CCN3, CCN4, CCN5, and
CCN6. These matricellular proteins play roles in regulating the
environment between cells [15e18]. All CCN proteins, except for
CCN5, are composed of four peptide motifs, i.e. insulin-like growth
factor-binding protein (IGFBP), von Willebrand factor type C repeat
(VWC), thrombospondin type 1 repeat (TSP1), and C-terminal
cystine-knot (CT) modules, which can bind a variety of key mole-
cules, such as IGFs, transforming growth factor -b (TGF-b), bone
morphogenetic proteins (BMPs), integrins, vascular endothelial
growth factor (VEGF), and Notch1, and play roles in regulating
many physiological processes [15,16,18]. CCN2 in particular medi-
ates multiple functions in a variety of tissues and organs by inter-
acting with multiple macromolecules. Its gene transcription is
upregulated by mothers against decapentaplegic homolog (SMAD)
mediated TGF-b signaling, in conjunction with signal transducer
and activator of transcription 3 (STAT3) [19,20]. In addition, CCN2
interacts with tropomyosin receptor kinase A (TRKA) and p75NTR
receptors, which are both neurotrophin responsive, and is itself a
ligand of NGF receptor [19,21,22].
In this study, we aimed to investigate molecular mechanisms
and pathways underlying the neurotrophic effects of jiadifenolide
in neuronal precursor cells derived from hiPSCs. We found that CCN
signaling pathways, especially that of CCN2, contributed to the
neurotrophic effects of jiadifenolide in human neuronal precursor
cells.2. Materials and methods
2.1. Preparation of jiadifenolide
Jiadifenolide was chemically synthesized and purified as previ-
ously reported [11,13]. We dissolved synthetic jiadifenolide in
dimethyl sulfoxide (DMSO).Table 1
Analysis of mRNA expressions between DMSO and jiadifenolide-treated neuronal precur
Gene DMSO
RPKM
TAGLN/SM22a (transgelin) 13.01± 1.39
ANXA2 (annexin A2) 5.82± 0.80
CTGF/CCN2 (connective tissue growth factor) 5.7± 0.22
IGFBP3 (insulin-like growth factor-binding protein 3) 4± 0.37
CYR61/CCN1 (cysteine-rich angiogenic inducer 61) 4.07± 0.45
SULF1 (sulfatase 1) 14.96± 1.44
MIR3620 12.48± 1.03
TP53 21± 0.56
ZIC3 (zinc finger protein of the cerebellum 3) 8.96± 0.43
MIR939 15.52± 1.42
ATP5EP2 (ATP synthase, Hþ transporting,
mitochondrial F1 complex, epsilon subunit pseudogene 2)
7.55± 0.15
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 332.75± 3.262.2. Culture of human induced pluripotent stem cells (hiPSCs)
Human induced pluripotent stem cell (hiPSC) line 201B7 (Cell
No. HPS0063) [23] was provided by Cell bank (Riken Bioresource
Center, Ibaraki, Japan). Cells were maintained on a mitomycin-C
(Kyowa Hakko Kirin, Tokyo, Japan)-treated mouse feeder cell
layer. For more details, please see Supplementary materials.
2.3. Induction and maturation of neuronal precursor cells from
hiPSC line 201B7
We differentiated neuronal precursor cells from hiPSC line
201B7 according to a method we have previously described [13].
Neuronal precursor cells were matured depending on treatment
conditions. Depending on treatment conditions, media was sup-
plemented with one of the following: 0.01% DMSO, neurotrophins
(a proteinmixture of 10 ng/mL recombinant human BDNF (rhBDNF;
Wako Pure Chemical Industries, Osaka, Japan), 10 ng/mL recombi-
nant human glial-cell derived neurotrophic factor (rhGDNF; Wako
Pure Chemical Industries) and 10 ng/mL recombinant human NT-3
(rhNT-3; Wako) [24]), 50 ng/mL recombinant human NGF (rhNGF;
Wako Pure Chemical Industries), 1 mM jiadifenolide, or 1, 10, 100 ng/
mL recombinant human CCN2 (rhCCN2; BioVendor, Brno, Czech
Republic). In cultures incubated for 23 days, media in wells was
changed every three days after plating. In cultures incubated for
five days, media in wells was changed at 24 and 72 h after plating.
For more details, please see Supplementary materials.
2.4. Other methods
We exhibited full methods and any associated references in
Supplementary materials.
3. Results
We have included the complete results and any relevant refer-
ences in the Supplementary materials.
3.1. Jiadifenolide activates CCN signaling in human neuronal cells
To investigate host factors in human neuronal precursor cells
that mediate jiadifenolide's neurotrophic effects, we performed
transcriptome analysis by comprehensive RNA sequencing of the
transcriptome of neuronal precursor cells derived from hiPSC line
201B7 incubated for 23 days with jiadifenolide [Table S1, deposited
in the DNA Data Bank of Japan (accession number DRA008385)]. As
shown in Table S1 and Table 1, Comprehensive RNA sequencingsor cells from hiPSCs line 201B7 by next-generation sequencing.
jiadifenolide Ratio (jiadifenolide per DMSO RPKM averages)
28.78± 1.37 2.21
11.93± 0.28 2.05
11.53± 0.45 2.02
7.4± 0.18 1.87
6.98± 0.50 1.72
24.95± 2.62 1.67
18.69± 0.3 1.50
17.29± 0.35 0.82
7.1± 0.42 0.79
10.04± 0.86 0.65
4.19± 0.63 0.56
320.34± 4.86 0.96
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alpha (SM22a), annexin A2 (ANXA2), CCN2, IGFBP3, and CCN1were
up-regulated greater than 1.5 fold in human neuronal cells,
whereas those of the TP53 was down-regulated to less than 0.85
fold in human neuronal cells by treatment with jiadifenolide rela-
tive to levels in DMSO treated cells.Fig. 1. Molecular network analysis using KeyMolnet of comprehensive RNA sequencing d
line 201B7. Using our comprehensive RNA sequencing data [deposited in the DNA Data Ban
0.01% DMSO- and 1 mM jiadifenolide-treated neuronal precursor cells derived from 201B7
transcriptional regulators of altered gene-expression were analyzed using KeyMolnet. (A) Mo
genes. The upper part of the panel shows the molecules that regulate gene expression. Gre
gene family. The lower part shows those molecules whose gene expression was altered. Th
mRNAs expressed in DMSO-treated cells, as revealed by comprehensive RNA analysis, are sho
predicted molecular pathways regulating altered gene expression in 1 mM jiadifenolide-treat
molecular network shown in panel (A) was compared with distinct canonical pathways in t
most significant contribution to the extracted network. Scores and p values were calculat
indicated below. SMAD: mothers against decapentaplegic homolog, SRC: steroid receptor coa
response factor.Next, transcriptional regulators were predicted by in silico mo-
lecular network analysis of the comprehensive RNA sequencing
results using KeyMolnet software (Tables S1:3) to identify molec-
ular pathways affected by jiadifenolide in human neuronal pre-
cursor cells. This analysis showed that the up-regulatedmRNA level
expression of CCN, CCN1, CCN2, SM22a, ANXA2, and IGFBP3 genesata from DMSO- and jiadifenolide-treated neuronal precursor cells from the hiPSC
k of Japan database (accession number DRA008385) and summarized in Table 1] from
cells after 23 days of incubation (n¼ 3 each), the molecular networks, pathways, and
lecular network of transcription factors influenced by jiadifenolide, and their regulated
en-framed circles in the upper part indicate transcription factors belonging to the CCN
e ratios of RPKM values of mRNAs expressed in jiadifenolide-treated cells, to those of
wn in red and blue to indicate up- and down-regulated molecules, respectively. (B) The
ed cells relative to 0.01% DMSO treated cells, and their calculated scores. The extracted
he KeyMolnet library. This makes it possible to identify canonical pathway making the
ed as described in experimental procedures. Abbreviations used in the list in (B) are
ctivator, C/EBP: CCAAT-enhancer-binding protein, VDR: vitamin D receptor, SRF: serum
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the regulation of SMAD, SMAD1, SMAD2, SMAD3, nuclear factor-kB
(NF-kB), and STAT3 or p53 which were up- or down-regulated by
jiadifenolide, respectively. In addition, KeyMolnet analysis indi-
cated relatively effects of jiadifenolide on CCN signaling, tran-
scriptional regulation by SMAD signaling pathway (Fig. 1B). These
results suggest that these defined signaling pathways may be up-
stream of the gene expression changes caused by jiadifenolide in
human neuronal precursor cells. The CCN signaling pathway may
be the main molecular pathway by which human neuronal pre-
cursor cells are affected by jiadifenolide, because many CCN familyFig. 2. Expression analysis by RT-qPCR of CCN family and SMAD-related genes in DMSO
analysis was used to evaluate transcription of CCN family and SMAD-related genes in neu
jiadifenolide for 23 days. Samples of the total RNA obtained for comprehensive transcriptome
for cDNA synthesis. Relative mRNA expression levels of CCN family molecules CCN1 (A), CCN
ANXA2 (H) (n¼ 3 each) were determined by RT-qPCR, normalized to levels of human GAPDH
Data represent means ± SEM. *p < 0.05 or **p < 0.01, versus DMSO-treated cells. n.s.: nottranscription factors [15,16,19], including CCN, CCN1, CCN2, SM22a,
and ANXA2 were up-regulated by treatment with jiadifenolide
(Table 1 and green-framed circles in Fig. 1A).
3.2. Jiadifenolide up-regulated CCN family members CCN1, CCN2,
and CCN6
CCN2 gene transcription is regulated by SMADswhich transduce
TGF-b and STAT3 signals [19,20]. SM22a, also known as transgelin,
is induced by TGF-b via SMAD3 protein [25]. To investigatewhether
jiadifenolide up-regulates the mRNA level expression of CCN familyand jiadifenolide-treated neuronal precursor cells from 201B7 cells. (AeH) RT-qPCR
ronal precursor cells derived from 201B7 cells incubated with 0.01% DMSO or 1 mM
analyses of cells treated with 0.01% DMSO- or 1 mM jiadifenolide for 23 days were used
2 (B), CCN3 (C), CCN4 (D), CCN5 (E), and CCN6 (F) or SMAD-related genes SM22a (G) and
, and expressed in relation to levels found in DMSO-treated cells (which were set to 1).
significant.
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CCN2, CCN3, CCN4, CCN5, and CCN6, and SM22a and AXNA2 in
DMSO- or jiadifenolide-treated human neuronal precursor cells by
RT-qPCR. Total RNA samples extracted for sequencing analysis
(Fig. 1) were also used for this RT-qPCR analysis. Expression levels
of CCN1 (Fig. 2A), CCN2 (Fig. 2B), CCN6 (Fig. 2F), SM22a (Fig. 2G), and
AXNA2 (Fig. 2H) mRNA were significantly up-regulated in
jiadifenolide-treated cells. Those of CCN3 (Fig. 2C), CCN4 (Fig. 2D),
and CCN5 (Fig. 2E) remained unchanged compared with DMSO-
treated cells. Interestingly, mRNA expression levels of CCN2
(Fig. 2B) and SM22a (Fig. 2G) in jiadifenolide-treated cells were
increased greater than 2 fold relative to those of DMSO-treated cellsFig. 3. Immunofluorescent staining of the dendrites of neuronal precursor cells from 2
dendrites, we performed immunofluorescent staining of human neuronal cells for MAP2, a ne
mL rhCCN2 (n¼ 6 each) for 23 days. Non-treated (NT) or neurotrophin treated (10 ng/mL rh
used as negative or positive controls, respectively. Cells were subsequently photographed und
Images in (A) were analyzed by NeuriteTracer [30]. Total neurite length (mm) (B) and n
means ± SEM of three independent experiments. *p < 0.05, *p < 0.01, and ***p< 0.001, comafter 23 days of incubation.
Taken together, these results showed that jiadifenolide activates
CCN signaling via up-regulating the mRNA level expression of the
CCN family members CCN1, CCN2, and CCN6, and CCN2 gene
expression may be the primary up-regulator of jiadifenolide
mediated CCN signaling.
3.3. CCN2 protein promoted neuronal dendritic outgrowth and
increased neuronal cell numbers in human neuronal precursor cells
We showed that jiadifenolide strongly induced transcription of
the CCN2 gene in human neuronal precursor cells (Table S1, Table 1,01B7 cells incubated with recombinant human CCN2 protein. To visualize neuronal
urite marker, and the nuclear stain DAPI. Each well was incubated with 1, 10, or 100 ng/
BDNF, 10 ng/mL rhGDNF, and 10 ng/mL rhNT-3) and 50 ng/mL rhNGF (n¼ 6 each) were
er a fluorescence microscope (A). The white scale bar in each image represents 100 mm.
umber of neurons (C) ((DAPI-positive cells) were measured. Data are presented as
pared with NT, respectively.
Fig. 4. Western blot analysis of p44/42 MAPK activation by recombinant human
CCN2 protein in neuronal precursor cells from 201B7 cells. Neuronal precursor cells
derived from 201B7 cells were treated with neurotrophins (10 ng/mL rhBDNF, 10 ng/
mL rhGDNF, and 10 ng/mL rhNT-3), and 50 ng/mL rhNGF or 1, 10, or 100 ng/mL rhCCN2
protein (n ¼ 3 each), respectively. NT (n ¼ 3) were used as negative controls. After five
days of incubation, protein expression and phosphorylation of p44/42 MAPK and p44/
42 MAPK were analyzed in each cell lysate by western blot (A). b-actin was used as a
protein loading control. Band intensities of phosphorylated and total p44/42 MAPK
proteins were measured. Ratios of phosphorylated/total p44/42 MAPK in each lysate
were determined relative to the ratio in NT-cells (set as 1) (B). Data are presented as
means ± SEM of two independent experiments. *p < 0.05 or ***p< 0.001 for com-
parisons with NT-cells.
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expression by jiadifenolide will contribute to its neurotrophic ef-
fects in human neuronal precursor cells. However, it remains un-
clear whether CCN2 protein will exert neurotrophic effects in
human neuronal precursor cells. To investigate whether CCN2
protein exhibits neurotrophic effects in human neuronal precursor
cells, we co-cultured neuronal precursor cells derived from 201B7
cells with 1, 10, or 100 ng/mL rhCCN2 protein. Neurotrophins or
recombinant human NGF (rhNGF) were used as positive controls,
and no treatment (NT) was used as a negative control. After 23 days
of co-culture, we performed immunofluorescent staining for
microtubule-associated protein 2 (MAP2; a neurite marker) and
used diamidino-2-phenylindole (DAPI) to stain nuclear DNA, to
evaluate the effect of CCN2 on neurite outgrowth and cell numbers.
Compared with NT, neurotrophins, rhNGF, and 1, 10, or 100 ng/mL
rhCCN2 protein promoted neurite extension (Fig. 3A), significantly
increasing total neurite length (Fig. 3B) in human neuronal cells.
These results demonstrated that jiadifenolide promotes dendrite
outgrowth in human neuronal cells. Additionally, treatment with
neurotrophins, rhNGF, or 1, 10, or 100 ng/mL rhCCN2 protein
significantly increased the number of human neuronal cells (DAPI-
positive cells) (Fig. 3C), suggesting that rhCCN2 protein promoted
cell growth or prevented cell death of human neuronal cells.
These results demonstrated that CCN2 protein exhibited similar
neurotrophic effects on human neuronal precursor cells as did
jiadifenolide.
3.4. CCN2 protein increased phosphorylation of p44/42 MAPK
protein in human neuronal precursor cells
MAPK-ERK signaling is one of the pathways activated by inter-
actionwith TRK receptors and neurotrophins, such as NGF, BDNF, or
NT3 [2]. The regulation of MAPK and CCN2 may be bidirectional,
with MAPK acting as upstream regulators of CCN2 and with CCN2
mediating MAPK phosphorylation. Mendes et al. reported that
CCN2 protein increases the phosphorylation level of p44/42 MAPK
protein, but not p38 or JUN N-terminal kinase (JNK; p54/46) MAPK
proteins in mouse neuronal progenitor cells after five days of cul-
ture in vitro [26]. Thus, we hypothesized that CCN2 protein may
induce neurotrophic effects in human neuronal precursor cells via
activation of p44/42 MAPK protein. To evaluate whether CCN2
protein activates p44/42 MAPK protein in neuronal precursor cells
derived from 201B7 cells, we analyzed total and phosphorylated
p44/42 MAPK levels after five days of co-culture with rhCCN2
protein by western blotting. Compared with NT controls, treatment
with neurotrophins or 100 ng/mL rhCCN2 protein significantly
increased the phosphorylation level of p44/42 MAPK protein in
human neuronal precursor cells (Fig. 4A and B).
These results demonstrate that CCN2 protein promotes phos-
phorylation of p44/42 MAPK protein in human neuronal precursor
cells, suggesting that CCN2 protein can induce neurotrophic effects
via activation of p44/42 MAPK signaling pathways.
4. Discussion
Neurotrophins, NGF, BDNF, NT-3, and GDNF, exert their effects
on neurons by each interacting with a different TRK or p75NTR re-
ceptor on the cell surface: NGF interacts with TRKA; BDNF interacts
with TRKB; NT3 interacts with TRKC; GDNF interacts with GDNF
family receptor a-1 (GFRa-1); p75NTR interacts with all neuro-
trophins extracellularly [2,9,27]. The binding of neurotrophins to
their receptors activates intracellular signaling pathways, such as
the MAPK-ERK pathway, the phosphoinositide 3-kinase-AKT
pathway, the phospholipase Cg1 (PLCg1)-protein kinase C (PKC)
pathway, the JUN pathway, and the HIF pathway, and therebypromotes neurite outgrowth and neuronal survival [2,9,27]. Acti-
vation of TRK receptors by binding to neurotrophins triggers
phosphorylation of their intracellular domain tyrosine residues via
autophosphorylation, which activates kinase activity. In the case of
the TRKA receptor, phosphorylation of tyrosine 490 activates
MAPK-ERK and PI3K-AKT signaling, whereas phosphorylation of
tyrosine 785 activates PLCg1-PKC signaling. In each case, adaptor
proteins, such as MAPK, PI3K, and PKC, are also activated by
phosphorylation [2]. By in silico molecular network analysis of our
comprehensive RNA sequencing results on jiadifenolide-treated
human neuronal cells using KeyMolnet software, we found that
jiadifenolide highly activated CCN signaling and transcriptional
regulation of SMAD (Fig. 1), and up-regulated mRNA expression of
CCN2 (Fig. 2B). These pathways activated by jiadifenolide are ex-
pected to contribute to neurotrophic effects via TRK receptor-
related signaling. The TRKA signaling pathway is especially
strongly suggested.
CCN2 protein mediates multiple functions in a variety of tissues
and organs by interacting with multiple molecules. It is induced by
a variety of transcription factors, such as SMAD, serum response
factor (SRF), NF-kB, activator protein-1 (AP-1), cAMP response
element binding protein (CREB), transcriptional coactivator with
PDZ-bindingmotif (TAZ), specific protein 1 (Sp1), hypoxia inducible
factor 1 alpha (HIF1a), Forkhead box class O3 a (FOXO3a) and STAT3
[16,19]. CCN2 protein can interact with neurotrophin receptor TRKA
and p75NTR receptors, and its ligand, NGF [19,21,22]. CCN2 protein
M. Shoji et al. / Biochemical and Biophysical Research Communications 519 (2019) 309e315 315stimulates phosphorylation of tyrosine 490 in TRKA, and promotes
phosphorylation of MAPK, JUK, and PKC in human mesangial cells
[19,21,22,28]. Khodosevich et al. reported that CCN2 expressed in
mouse olfactory bulb (OB) by adeno-associated virus (AAV) regu-
lates survival of neurons in the mouse OB by apoptosis of immature
neurons via TGF-b2eSMAD signaling by in vivo analysis at four and
eight weeks [29]. In addition, Mendes et al. reported that CCN2
protein promotes phosphorylation of p44/42 MAPK protein in
mouse neuronal progenitor cells, but not p38 or p54/46 MAPK
proteins, and induces astrogenesis in mouse primary embryonic
neural cells in five day cultures as assessed by in vitro analysis [26].
We showed that rhCCN2 protein exhibited neurotrophic effects and
promoted phosphorylation of p44/42 MAPK protein in human
neuronal precursor cells (Figs. 3 and 4). Therefore, CCN2 protein can
induce neurotrophic effects via activation of p44/42 MAPK
signaling.
We found that jiadifenolide up-regulated mRNA level expres-
sion of not only CCN2 but also CCN1 (Table 1 and Fig. 2A) and CCN6
genes (Fig. 2F). In Supplementary materials, we discussed the re-
lationships of CCN1 or CCN6 against neurotrophic effects in human
neuron.
Taken together, jiadifenolide promotes transcription of the
CCN2 gene via various transcription factors, and the expressed
CCN2 protein induces neurotrophic effects through TRKA and/or
p75NTReMAPK signaling pathways. In conclusion, the findings in
this study reveal the molecular mechanisms and signaling path-
ways underlying jiadifenolide's neurotrophic effects in human
neurons for the first time. This is the first discovery to connect
neurotrophic effects with CCN signaling.
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